NEW Our free Dividend Tracker is live — see what your stocks pay you

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

Start Free »

SRPT | NASDAQ

$17.77 $0.94 | 5.59%

TREND SIGNAL: Signal available — unlock to view

|2026-09-08

Add to favoritesFavorite

Company Overview:

Market Cap: $1.78B

Trailing PE: N/A

FWD PE *: 31.9x

Payout Ratio (TTM): —

52-Week Range: $14.68 - $24.68

* Forward PE is based on street estimates.

7.7 Year SRPT Performance Metrics:

Total Return (with DRIP): -87.3% (-23.49% CAGR)

Total Return (no DRIP): -87.3% (-23.49% CAGR)

Share Price: -87.3% (-23.49% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $1,272

Total Return $ (with DRIP): -$8,728

SRPT Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

SRPT Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

SRPT Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

SRPT - Revenue

SRPT Revenue CAGR:1Y: -34.34%2Y: 5.15%5Y: 19.58%10Y: 0.00%

SRPT - Earnings Per Share (EPS)

SRPT EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - Net Income

🔓 See the full chart40% off right now · 7-day free trial

SRPT Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

SRPT EBITDA CAGR:1Y: -82.22%2Y: 58.36%5Y: 0.00%10Y: 0.00%

SRPT - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

SRPT Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

SRPT Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

SRPT Operating Income CAGR:1Y: -88.50%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

SRPT Gross Profit CAGR:1Y: -45.07%2Y: -9.81%5Y: 11.74%10Y: 0.00%

SRPT - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

SRPT Shares Outstanding CAGR:1Y: -1.12%2Y: 5.56%5Y: 5.74%10Y: 8.61%

SRPT - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

SRPT Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

SRPT Stock-Based Comp CAGR:1Y: 45.50%2Y: 3.30%5Y: 13.21%10Y: 22.94%

SRPT - Expenses

🔓 See the full chart40% off right now · 7-day free trial

SRPT Expenses CAGR:1Y: -91.76%2Y: -69.94%5Y: -14.87%10Y: 12.99%

SRPT - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

SRPT - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

SRPT - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

SRPT - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

SRPT - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

SRPT - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

SRPT - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

SRPT Revenue CAGR:1Y: -34.34%2Y: 5.15%5Y: 19.58%10Y: 0.00%

SRPT - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

SRPT Revenue CAGR:1Y: -34.34%2Y: 5.15%5Y: 19.58%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

SRPT - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

SRPT Actual Revenue CAGR:1Y: -34.34%2Y: 5.15%5Y: 19.58%10Y: 0.00%

SRPT - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

SRPT Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

SRPT Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

SRPT Actual EBITDA CAGR:1Y: -82.22%2Y: 58.36%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

SRPT - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

SRPT Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

SRPT Gross Profit Margin CAGR:1Y: -16.35%2Y: -14.23%5Y: -6.56%10Y: 0.00%

SRPT - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

SRPT Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

SRPT Price To Sales Ratio CAGR:1Y: 72.17%2Y: -66.01%5Y: -34.03%10Y: 0.00%

SRPT - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

SRPT Return on Capital Employed CAGR:1Y: -88.18%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SRPT - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

SRPT Return on Invested Capital CAGR:1Y: -88.18%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for SRPT

Based on past 7.7-year performance, here are SRPT growth metrics:

Share price CAGR of -23.49%
Dividend CAGR of +0%

Using SRPT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	SRPT (DRIP)	SRPT - No DRIP
Current Price	$17.77	$17.77
Start Shares	562.75	562.75
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	562.75	562.75
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$1.22	$17.77
Total Dividends	$0	$0
Final Value	$687	$10,000

Estimated Future Value + Dividends - SRPT

NOTE: Above numbers are our estimate based on SRPT's Dividend and Price CAGR over past 7.7 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

Company Info

Sarepta Therapeutics, Inc. (SRPT) had its IPO on 1997-06-04, and is traded on NASDAQ stock exchange.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

SRPT website: https://www.sarepta.com

Get Full Access to All Reports with DRIPCalc PRO

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

DCF Model — SRPT

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $17.77

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →